HUNTINGTON'S DISEASE THERAPEUTIC COMPOUNDS

(19)

(11)

EP 3 146 051 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	27.11.2019 Bulletin 2019/48

(45)	Mention of the grant of the patent:
	04.09.2019 Bulletin 2019/36

(21)	Application number: 15795373.8

(22)	Date of filing: 20.05.2015

(51)

International Patent Classification (IPC):

C12N 15/113^(2010.01)

A61K 31/7088^(2006.01)

(86)	International application number:
	PCT/US2015/031783

(87)	International publication number:
	WO 2015/179525 (26.11.2015 Gazette 2015/47)

(54)	HUNTINGTON'S DISEASE THERAPEUTIC COMPOUNDS THERAPEUTISCHE VERBINDUNGEN FÜR HUNTINGTON-KRANKHEIT COMPOSÉS THÉRAPEUTIQUES POUR LA MALADIE DE HUNTINGTON

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

20.05.2014 US 201462000895 P

(43)	Date of publication of application:
	29.03.2017 Bulletin 2017/13

(73)	Proprietor: University of Iowa Research Foundation
	Iowa City, IA 52242 (US)

(72)	Inventors:
	DAVIDSON, Beverly, L. Iowa City, Iowa 52242 (US) MAS MONTEYS, Alejandro Iowa City, Iowa 52242 (US)

(74)	Representative: PATERIS Patentanwälte PartmbB
	Altheimer Eck 13 80331 München 80331 München (DE)

(56)

References cited: :

WO-A1-2012/109667
WO-A2-2008/134646
US-A1- 2009 004 668
US-A1- 2010 291 673

WO-A1-2014/007858
WO-A2-2008/150897
US-A1- 2009 130 751
US-A1- 2013 281 372

J. L. MCBRIDE ET AL.: "Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, vol. 105, no. 15, 15 April 2008 (2008-04-15), pages 5868-5873, XP055424282, US ISSN: 0027-8424, DOI: 10.1073/pnas.0801775105

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).